The shares of fast-growing biotech company Impedimed Limited (ASX: IPD) rocketed higher by as much as 10% this morning following the release of a positive announcement to the market.
The announcement revealed that a new study published in the Frontiers in Oncology journal demonstrates the impact that the company’s L-Dex lymphoedema detection product can have on patients that are at risk from breast cancer related lymphoedema.
The retrospective study followed 326 patients which had undergone either an axillary lymph node dissection or a sentinel lymph node biopsy with a median follow-up time of 21.7 months. Patients were monitored with L-Dex measurements as part of their routine post-operative follow-up.
The cumulative incidence of sub-clinical lymphoedema was 4.3% for sentinel lymph node biopsy patients and 26.7% for axillary lymph node dissection patients. Very positively L-Dex allowed for early intervention for these patients, which resulted in a reduction of persistent, clinical lymphoedema by 99.5% and 91.4% respectively.
According to the release the study concluded that:
“The results of this retrospective study demonstrate that L-Dex assessments can be incorporated into routine breast cancer programs as part of follow-up. This is critically important given the recent changes in the NCCN survivorship guidelines for post-treatment follow-up care for breast cancer patients establishing that health-care providers educate, monitor, and refer for lymphedema management.”
Clearly this is a very positive step forward for L-Dex and it comes as little surprise to see its shares bolt higher. If L-Dex is incorporated into routine breast cancer programs then ImpediMed is in a great position to prosper.
But let’s not forget that it is still early days for both L-Dex and its recently launched health and wellness tracker SOZO. As a result I would suggest restricting any investment in the company to just a small part of your portfolio.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.